title: A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
abstract: BACKGROUND
  Advanced renal cell cancer (RCC) continues to have a poor overall prognosis despite new FDA-approved therapies. Although taxane-based therapies are generally ineffective in RCC, research into the role of the von Hippel-Lindau protein has shown an association with microtubule dynamics. Mitotic kinesins are a class of molecular motors that also interact with microtubules and are required for proper mitotic function. SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death.
  
  
  METHODS
  Twenty patients with previously treated advanced RCC were enrolled on this phase II trial of SB-715992, with response rate as a primary endpoint.
  
  
  RESULTS
  No patients responded with complete or partial remission. Six patients had stable disease, and 1 patient continues on therapy after 12 cycles. Common toxicities included anemia (80%), elevated creatinine (70%), lymphopenia (45%), fatigue (50%), hyperglycemia (50%), and dyspnea (45%). Reported grade 3/4 toxicities included dyspnea, fatigue, neutropenia with skin infection, dizziness, hyperuricemia, and hypertension.
  
  
  CONCLUSIONS
  This dose and schedule of SB-715992 does not appear to have a significant cytotoxic effect for patients with previously treated advanced RCC.
authors.affiliation: Department of Medicine, Section of Hematology/Oncology, The University of Chicago, IL 60637, USA.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Lee
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Beekman
authors.forename: Maha
authors.initials: M
authors.lastname: Hussain
authors.forename: Nancy B
authors.initials: NB
authors.lastname: Davis
authors.forename: Joseph I
authors.initials: JI
authors.lastname: Clark
authors.forename: Sachdev P
authors.initials: SP
authors.lastname: Thomas
authors.forename: Katherine F
authors.initials: KF
authors.lastname: Nichols
authors.forename: Walter M
authors.initials: WM
authors.lastname: Stadler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002641:Chicago; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*; D012449:Safety; D014495:Universities
chemical_list: D001549:Benzamides; D011799:Quinazolines; C508757:ispinesib